Results 81 to 90 of about 98,054 (191)

A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries.

PLoS ONE
Several literature review studies have been conducted on cost-effectiveness threshold values. However, only a few are systematic literature reviews, and most did not investigate the different methods, especially in-depth reviews of directly eliciting WTP
Anh Nu Vu, Minh Van Hoang, Lars Lindholm, Klas Göran Sahlen, Cuc Thi Thu Nguyen, Sun Sun   +5 more
doaj   +1 more source

The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health

Journal of Comparative Effectiveness Research
Since late 2020, the Canadian Agency of Drugs and Technologies in Health (CADTH) has been using a threshold of $50,000 (CAD) per quality-adjusted life-year (QALY) for both oncology and non-oncology drugs. When used for oncology products, this threshold
Chakrapani Balijepalli, Lakshmi Gullapalli, Juhi Joshy, Nigel SB Rawson   +3 more
doaj   +1 more source

QALY delusions [PDF]

Psychiatric Bulletin, 1992
Adrian James, Tessa Cook, Arden Tomison
openaire   +1 more source

Value of a QALY and VSI estimated with the chained approach

European Journal of Health Economics, 2019
S. Olofsson, Ulf-G. Gerdtham, Lars Hultkrantz, U. Persson   +3 more
semanticscholar   +1 more source

Toward a Consensus on the QALY

Качественная клиническая практика, 2018
.
Michael Drummond, Diana Brixner, Marthe Gold, Paul Kind, Alistair Mcguire, Erik Nord, I. A. Vilum, D. Yu. Belousov   +7 more
doaj  

Valuing Mortality Risk Reductions and Health Improvements: A Life Expectancy Framework to Harmonize Policy Traditions. [PDF]

Risk Anal
Nielsen JS, Chilton S, McDonald R.
europepmc   +1 more source

The Impact of Hepatitis C and Socio-Demographic Variables on Health-Related Quality of Life in Pakistan: Cross-Sectional Study. [PDF]

J Viral Hepat
Niyomsri S, Lim AG, Arif A, Asim M, Chaudhry A, Choudhry N, Hasnain A, Kemos P, Metcalfe C, Choudhry A, Hamid SS, Niaz S, Qureshi H, Foster GR, Vickerman P, Walker JG, HepFreePak team.   +16 more
europepmc   +1 more source

Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention in heart failure with reduced ejection fraction: a Markov model using JROAD-DPC cost data in Japan. [PDF]

Front Cardiovasc Med
Ohashi K, Watanabe M, Morii Y, Yokoshiki H, Kusano K, Imai K, Takagi M, Yamane T, Tada H, Ogasawara K.   +9 more
europepmc   +1 more source

The Paradox of Life Extension with Traditional Cost-Effectiveness Analysis: A Case Study with Duchenne Muscular Dystrophy. [PDF]

J Health Econ Outcomes Res
Sedita L, Klimchak A, Perfetto E, Gooch K, Malone DC.   +4 more
europepmc   +1 more source

Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis. [PDF]

Ther Adv Med Oncol
Wang J, Ding B, Jing Z, Zhu Y, Gao L, Yao H, Tao T, Li X.   +7 more
europepmc   +1 more source